Kemp Dolliver
Director of Research Brookline Capital Markets
Kemp Dolliver, CFA
Director of Research & Senior Biotechnology Analyst
Kemp Dolliver is the Director of Research and a Senior Analyst at Brookline. Mr. Dolliver has extensive healthcare experience across multiple sell-side and buy-side roles in the U.S and Asia. Previously, he was the Founder and Chief Investment Officer of Cherrystone Hill Capital Management, LLC, which specialized in investing in listed healthcare companies across the world’s emerging markets. As a sell-side analyst, Mr. Dolliver was a Managing Director at Religare Capital Markets Pte. Ltd., Avondale Partners LLC, and Cowen Inc. His buy-side roles have included portfolio management positions at both Aetna and Bank of America. The Wall Street Journal has recognized him four times for his stock picking abilities in its “Best on the Street” survey.
Seminars
- Identifying the scientific, clinical and commercial characteristics investors believe will differentiate tomorrow’s category leaders from an increasingly crowded pipeline
- Exploring which risks remain most significant to investment decisions, from manufacturing scalability and reimbursement to target differentiation and regulatory execution
- Evaluating the milestones that create the greatest enterprise value and discussing where capital should be deployed to maximise long-term commercial success
